Enveric Biosciences, Inc.
ENVBNasdaq
$1.34
↓ -1.5%Jul 17 close · end-of-day
Price
1Y↓ -91.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.0M
Enterprise Value
$2.0M
P/E
—
P/S
—
P/B
0.4
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
$12.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
250.0%
ROIC
-128.3%
Debt / Equity
—
Net Cash
—
Return 1Y
-91.3%
Company profile
Enveric Biosciences, Inc. engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 for the. treatment of cancer related distress. EV102, a cannabinoid cream for topical skin application; and EV101, a. cannabinoid and chemotherapy combination therapy.
- CEO
- Joseph Tucker
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- Florida
- Website
- enveric.com
Management & directors
- Coveney Kevin MichaelChief Financial Officer
- Facchini Peter J.Chief Innovation Officer
- Tucker Joseph EdwardChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
ENVB Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.08↓ -92.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$5.6M | -$64.6M | -$27.4M | -$16.4M | -$9.6M | -$8.8M |
| Net income | -$6.9M | -$49.0M | -$18.5M | $17.5M | $9.6M | $12.1M |
| Diluted EPS | — | — | -$13.00 | -$121.29 | -$228.48 | -$36.24 |
| Operating cash flow | -$3.9M | -$11.5M | -$17.1M | -$14.1M | -$7.7M | -$8.1M |
| Free cash flow | — | -$11.6M | -$17.7M | -$14.1M | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.9M | -$2.1M | -$3.2M | -$2.2M | -$2.5M | -$1.9M | -$2.2M | -$1.6M |
| Net income | -$1.9M | -$2.1M | $16.0M | -$2.2M | -$2.5M | -$1.9M | $18.7M | -$1.6M |
| Diluted EPS | -$3.72 | -$43.10 | -$172.45 | -$14.58 | -$0.97 | -$10.81 | -$9.88 | -$1.08 |
| Operating cash flow | -$2.9M | -$927,070.00 | -$1.3M | -$2.4M | -$1.9M | -$2.1M | -$1.8M | -$2.3M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 16, 2026
Jun 9, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-01 | Coveney Kevin Michael· Chief Financial Officer | Award | 133,333 | $0.00 | $0.00 | filing |
| 2026-06-01 | Tucker Joseph Edward· Chief Executive Officer | Award | 201,124 | $0.00 | $0.00 | filing |
| 2026-06-01 | PASQUALONE FRANK | Award | 18,518 | $0.00 | $0.00 | filing |
| 2026-06-01 | WEBB MICHAEL D | Award | 18,518 | $0.00 | $0.00 | filing |
| 2026-06-01 | Schabacker Marcus | Award | 18,518 | $0.00 | $0.00 | filing |
| 2026-06-01 | Kegler George A. | Award | 18,518 | $0.00 | $0.00 | filing |
| 2026-06-01 | DeWitt Sheila | Award | 18,518 | $0.00 | $0.00 | filing |
| 2026-06-01 | Facchini Peter J.· Chief Innovation Officer | Award | 25,000 | $0.00 | $0.00 | filing |
| 2025-12-23 | DeWitt Sheila | Award | 7,633 | $0.00 | $0.00 | filing |
| 2025-12-23 | Kegler George A. | Award | 7,633 | $0.00 | $0.00 | filing |
| 2025-12-23 | PASQUALONE FRANK | Award | 7,633 | $0.00 | $0.00 | filing |
| 2025-12-23 | Schabacker Marcus | Award | 7,633 | $0.00 | $0.00 | filing |
| 2025-12-23 | Tucker Joseph Edward· Chief Executive Officer | Award | 60,296 | $0.00 | $0.00 | filing |
| 2025-12-23 | WEBB MICHAEL D | Award | 7,633 | $0.00 | $0.00 | filing |
| 2025-12-23 | Coveney Kevin Michael· Chief Financial Officer | Award | 40,198 | $0.00 | $0.00 | filing |
Latest 15 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.